The Weekly Dose: Hantavirus Outbreak, FDA Controversies, and RFK Jr’s Antidepressant Push

In this episode of The Weekly Dose, host Danielle Valletti breaks down major stories shaping pharmacy practice, public health, and health policy.

The World Health Organization confirmed that the hantavirus outbreak aboard the MV Hondius cruise ship involves the Andes strain—the only known human-transmissible form of hantavirus. The outbreak has resulted in multiple confirmed and suspected cases, several deaths, and growing concerns regarding close-contact transmission aboard the ship.

Reporting by the New York Times revealed that FDA officials blocked the publication of several agency-backed studies supporting the safety of COVID-19 and shingles vaccines, prompting criticism from outside experts and renewed debate surrounding scientific transparency and vaccine communication.

The Wall Street Journal also reported that President Donald J. Trump has pressured FDA Commissioner Marty Makary to move more quickly on approving flavored vape and nicotine products, reigniting discussions around youth vaping risks, harm reduction, and FDA regulatory authority.

Additionally, Health Secretary Robert F. Kennedy Jr announced several initiatives aimed at helping Americans taper off antidepressants, particularly selective serotonin reuptake inhibitors, through new trainings, reimbursement pathways, and deprescribing guidance.